Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024

  • Post author:
  • Post category:

Eight new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended eight medicines for approval at its November 2024 meeting.The committee recommended granting a conditional marketing authorisation for Augtyro (repotrectinib),…

Continue ReadingMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024

Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids

  • Post author:
  • Post category:

After re-examining its initial opinion, EMA recommends updating the advice aimed at minimising the risks of interaction between the weight loss medicine Mysimba (naltrexone/bupropion) and opioid-containing medicines (including painkillers such…

Continue ReadingUpdated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids